Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6054560
Mitogen activated protein kinase, FRK
expired -
US 6054485
Eye treatments using synthetic thyroid hormone compositions
expired -
US 6051227
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
expired -
US 6051693
CLNH11-specific antibodies
expired -
US 6051396
Method for producing retinoblastoma gene protein products
expired -
US 6051598
Amino ceramide-like compounds and therapeutic methods of use
expired -
US 6051229
Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions
expired -
US 6051387
Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
expired -
US 6051230
Compositions for targeting the vasculature of solid tumors
expired -
US 6051218
Tumor radiosensitization using gene therapy
expired -
US 6051232
Chimeric MHC class I antigens for inducing allograft tolerance
expired -
US 6048535
Multivalent in ovo avian vaccine
expired -
US 6048534
Methods and compositions for the selective regulation of chorionic prostanoids
expired -
US 6045815
Parenteral pimaricin as treatment of systemic infections
expired -
US 6046241
.beta.-alethine as anti-tumor agent
expired -
US 6046015
Modulating Robo: ligand interactions
expired -
US 6046158
Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
expired -
US 6046007
Method and composition for regulating apoptosis
expired -
US 6045807
Method for production of neuroblasts
expired -
US 6044981
Microfabricated filter with specially constructed channel walls, and containment well and capsule constructed with such filters
expired -
US 6042829
Biotherapy of cancer by targeting TP-3/P80
expired -
US 6042846
Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides
expired -
US 6042833
Cellular internalization of pIgR stalk and associated ligands
expired -
US 6043082
Regulated transcription of targeted genes and other biological events
expired -
US 6043225
Diagnosis and treatment of arterial chlamydial granuloma
expired -
US 6043345
IgE isoforms and methods of use
expired -
US 6043062
Constitutively active phosphatidylinositol 3-kinase and uses thereof
expired -
US 6043223
Enhanced opening of abnormal brain tissue capillaries
expired -
US 6042610
Meniscal augmentation device
expired -
US 6043390
Pentaerythritol lipid derivatives and nucleic-acid complexes
expired -
US 6040340
Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
expired -
US 6040293
Clavanins
expired -
US 6040332
Amino ceramide-like compounds and therapeutic methods of use
expired -
US 6036955
Kits and methods for the specific coagulation of vasculature
expired -
US 6034255
Inhibitors of cholesterol esterase
expired -
US 6034065
Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
expired -
US 6033894
Kaposi's Syndrome Herpesvirus protease and assembly protein compositions and methods
expired -
US 6033864
Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
expired -
US 6033644
Biomodulators as universal imaging agents
expired -
US 6033688
Cystic fibrosis therapy
expired -
US 6034109
Method for protection of heart by limiting metabolic and ionic abnormalities developed during ischemia following ischemia or resulting from ischemia
expired -
US 6030995
Amino ceramide-like compounds and therapeutic methods of use
expired -
US 6030974
Method of anesthesia
expired -
US 6030968
Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
expired -
US 6030830
Immunoglobulin trans-spliced transcripts and uses thereof
expired -
US 6028054
Method for increasing bioavailability of oral pharmaceutical compositions
expired -
US 6027888
Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
expired -
US 6027737
Treatment for osteoporosis using potassium salts
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory